4594.T
BrightPath Biotherapeutics Co.,Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 52.00
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -27.2%
- EPS
- +4.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -100.0%
- EBITDA
- —
- EPS
- +4.9%
Three-year CAGR
- Revenue
- -59.5%
- EBITDA
- —
- EBIT
- -0.4%
- Net income
- +1.5%
- EPS
- +22.5%
- Free cash flow
- -7.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026